K562/GM-CSF VACCINATION

K562/GM-CSF 疫苗接种

• 批准号: 7378863
• 负责人: HYAM Isaac LEVITSKY
• 金额: $ 0.9万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378863
• 关键词: K562; GM; CSF; VACCINATION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Description of Project for Release to Public- 03-08-12-05 CML is thought to an immunologically responsive disease based on the ability to cure the disease with allogeneic T cells as well as the demonstration of host immune responses to CML-associated antigens in patients who have responded to interferon-alpha. The dramatic clinical responses obtained with the selective tyrosine kinase inhibitor Imatinib Mesylate has provided a relatively non-toxic cytoreductive therapy, although complete molecular remissions remain rare. In this study, we are vaccinating CML patients who are in a complete hematologic remission, but have persistent cytogeneic or molecular evidence of disease, with a novel allogeneic tumor cell-based vaccine that expresses many of the antigens shown to be present in CML cells and to which T cell responses have been demonstrated. The vaccine is administered in conjunction with a topical agonist to Toll Like Receptor 9 (imiquimod). The two major objectives of this study will be to demonstrate the ability to generate and augment CML specific T cell responses in patients vaccinated while in remission on imatinib, and to test the hypothesis that such responses will lead to a measurable reduction in tumor burden (or its elimination) as assayed by quantitative RT-PCR of bcr/abl transcripts.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。向公众发布的项目描述 - 03-08-12-05 CML 被认为是一种免疫反应性疾病，基于同种异体 T 细胞治愈该疾病的能力以及在体内对 CML 相关抗原的宿主免疫反应的证明对干扰素-α有反应的患者。尽管完全分子缓解仍然罕见，但选择性酪氨酸激酶抑制剂甲磺酸伊马替尼获得的显着临床反应提供了相对无毒的细胞减灭疗法。在这项研究中，我们为处于完全血液学缓解但具有持续的细胞遗传学或分子疾病证据的 CML 患者接种一种新型同种异体肿瘤细胞疫苗，该疫苗表达 CML 细胞中存在的许多抗原，并且T 细胞对此的反应已得到证实。该疫苗与 Toll 样受体 9（咪喹莫特）的局部激动剂联合施用。这项研究的两个主要目标是证明在接受伊马替尼缓解期间接种疫苗的患者中产生和增强 CML 特异性 T 细胞反应的能力，并检验这种反应将导致肿瘤负荷显着减少（或通过 bcr/abl 转录物的定量 RT-PCR 进行测定。